Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-02

Clinical Trial Update: A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ClariVein with a sclerosing agent for venous insufficiency has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ClariVein (not specified)

Snippet

Sponsor: Vascular Insights, LLC | Conditions: Venous Insufficiency | Phase 2 | Status: TERMINATED | Results posted: 2022-03-02